Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;3(6):341-54.
doi: 10.1177/2040620712459746.

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians

Claire Harrison  1 , Alessandro M Vannucchi
Affiliations

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians

Claire Harrison et al. Ther Adv Hematol. 2012 Dec.

Abstract

Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.

Keywords: JAKafi; janus kinase 2; myelofibrosis; myeloproliferative neoplasm; ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Alessandro M. Vannucchi have received honoraria for participation to Scientific advisory board by Novartis and Italfarmaco. Claire Harrison is Speaker for Shire, Novartis, Cellgene, Sanofi Avensis.

Figures

Figure 1.
Figure 1.
Magnetic resonance imaging from a patient before and after 72 weeks of ruxolitinib therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdel-Wahab O., Pardanani A., Rampal R., Lasho T., Levine R., Tefferi A. (2011) DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25: 1219–1220 - PMC - PubMed
    1. Bacigalupo A., Soraru M., Dominietto A., Pozzi S., Geroldi S., Van Lint M., et al. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45: 458–463 - PubMed
    1. Baffert F., Regnier C., De Pover A., Pissot-Soldermann C., Tavares G., Blasco F., et al. (2010) Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 9: 1945–1955 - PubMed
    1. Barosi G., Birgegard G., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H, et al. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemianet Consensus Conference. Blood 113: 4829–4833 - PubMed
    1. Barosi G., Mesa R., Thiele J., Cervantes F., Campbell P., Verstovsek S., et al. (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22: 437–438 - PubMed